Objective: To evaluate the efficacy and side effects of Diphereline 11,25mg in treatment of unresectable advanced prostatic cancer at Department of Urology, No.103 Military Hospital. Subject and method: 37 prostatic cancer patients underwent hormone therapy with Diphereline at Department of Urology, No.103 Military Hospital from January 2012 to June 2014. Hormone therapy was indicated in patients with unresectable extensive prostatic cancer or with postoperative recurrent disease. Patients received Diphereline 11.25 mg via intramuscular injection every 3 months. Clinical characteristics (age, disease duration, the main symptoms), blood level of PSA and testosterol variation were assessed. Improvement of clinical symptoms and side effects of the drug were recorded. Result: Average age was 75.6 (54-88). 7 patients (18.9 percent) had bone metastases at the time of diagnosis. Surrounding tissues were invaded in 21 patients (56.8 percent). Blood PSA levels were over measurement range in 7 patients (18.9 percent). Diagnosis of prostate cancer: Based on rectal biopsy in 4 patients (10.8 percent); 2 patients with recurrence after radical prostatectomy due to prostate cancer (5.4 percent); 31 patients were diagnosed by transurethral prostatectomy (83.8 percent). Blood PSA levels decreased to normal after 3 months in 35 patients (94.6 percent) and after 6 months in 100 percent of patients. Clinical signs of improvement were seen in 100 percent of patients. 3 patients (8.1 percent) developed a drug resistance in 15 and 24 months after treatment. Conclusion: Treatment of distant metastasis or inoperable prostate cancer with Diphereline 11.25mg showed good results in 91.9 percent of cases. The drug were efficient in improvement of pain and local invasion.
- Đăng nhập để gửi ý kiến